Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

50.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.0K
Subviral Agents01:29

Subviral Agents

668
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
668

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Split Reporter Systems in Viral Protein-Protein Interactions and Multimerization: Mechanisms and Applications.

Cells·2026
Same author

Use of the Split Luciferase Complementation Assay to Identify Novel Small Molecules That Disrupt Essential Protein-Protein Interactions of Viruses.

Biomolecules·2025
Same author

I Died-and Was Brought Back to Life-Twice.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

The role of the 3'-UTR of the chemokine receptor CCR2 and hnRNPA0 in regulating mRNA stability and subcellular distribution in human CD4<sup>+</sup> T cells.

Frontiers in immunology·2025
Same author

Targeting CCR5: A central approach to HIV treatment and cure strategies.

Virology·2024
Same author

30 years of HIV therapy: Current and future antiviral drug targets.

Virology·2024

Related Experiment Video

Updated: Feb 28, 2026

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

8.3K

Next-Generation HIV-1 Therapeutics in Co-Endemic Settings.

Brandon Ngo1, Richard E Sutton1

  • 1Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, 300 Cedar St., New Haven, CT 06520, USA.

Biomedicines
|February 27, 2026
PubMed
Summary
This summary is machine-generated.

Next-generation HIV-1 therapies must account for co-infections with arboviruses and mammarenaviruses common in South America. This "co-infection-aware" approach is crucial for durable HIV-1 control and developing effective global interventions.

Keywords:
ARTHIV-1 therapeuticsarbovirusesbroadly neutralizing antibodiesco-endemic viral infectionsimmune activationlong-acting injectablenext-generation antiretroviralsreservoir dynamics

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.5K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.5K

Related Experiment Videos

Last Updated: Feb 28, 2026

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

8.3K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.5K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.5K

Area of Science:

  • Infectious Diseases
  • Virology
  • Immunology

Background:

  • Lifelong antiretroviral therapy (ART) for HIV-1 has limitations.
  • Next-generation HIV-1 treatments aim to overcome these challenges.
  • South American HIV-1 epidemics overlap with arboviruses and mammarenaviruses, leading to co-infections.

Purpose of the Study:

  • To review the intersection of HIV-1 and endemic viral co-infections in South America.
  • To evaluate the performance of novel HIV-1 therapeutics in co-infection contexts.
  • To propose a "co-infection-aware" therapeutic development strategy for durable HIV-1 control.

Main Methods:

  • Synthesis of clinical and translational evidence.
  • Evaluation of emergent HIV-1 agents (capsid inhibitors, long-acting injectables, maturation inhibitors, broadly neutralizing antibodies).
  • Analysis of co-infection impact on drug pharmacokinetics, immune activation, and disease progression.

Main Results:

  • Co-infections profoundly impact immune activation and organ function, altering drug pharmacokinetics.
  • These factors can compromise ART efficacy, promote resistance, and affect latent reservoir dynamics.
  • Current next-generation HIV-1 therapies may face challenges in co-infection settings.

Conclusions:

  • HIV-1 therapeutic development must be "co-infection-aware" to achieve durable control and progress toward a cure.
  • Clinical trials need to incorporate co-infection endpoints and preclinical models must reflect real-world exposures.
  • Integrating regional viral ecology is essential for developing globally effective HIV-1 interventions.